Drug · CHEMBL708
Trials124
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
1 to 20 of 124
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00312494 | 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects | Phase 3 | 680 | 2010-01-22 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00254202 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia | Phase 3 | 593 | 2024-12-13 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00280566 | Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed) | Phase 3 | 584 | 2009-12-14 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT01211522 | The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study | Phase 3 | 566 | 2019-08-20 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00141271 | A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression | Phase 3 | 536 | 2009-03-24 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00633399 | Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs | Phase 2 | 458 | 2014-07-03 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00282464 | A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression. | Phase 3 | 392 | 2009-06-02 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00723606 | A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation | Phase 3 | 376 | 2010-08-25 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00330863 | Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy | Phase 4 | 357 | 2018-07-10 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00139737 | Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia | Phase 3 | 344 | 2010-07-14 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00483548 | Adjunctive Ziprasidone in the Treatment of Bipolar I Depression | Phase 3 | 298 | 2010-02-23 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00257192 | Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia | Phase 3 | 284 | 2010-04-13 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00406315 | Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone | Phase 4 | 255 | 2010-02-02 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00257166 | Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) | Phase 3 | 238 | 2013-07-19 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00265382 | Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia | Phase 3 | 221 | 2010-05-19 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00044655 | Switching Medication to Treat Schizophrenia | Phase 4 | 219 | 2013-12-05 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00748566 | One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome | Phase 4 | 172 | 2013-06-19 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT02075047 | Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder | Phase 3 | 171 | 2021-04-01 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00265330 | Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) | Phase 3 | 169 | 2009-04-03 | ziprasidone | Its name | ClinicalTrials.gov |
| NCT00403546 | High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms | Phase 3 | 131 | 2017-06-06 | ziprasidone | Its name | ClinicalTrials.gov |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL708/trials